Q3 FY26 results: Onesource posts consolidated loss of Rs 887M
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.1 pts less than Nifty Smallcap 250 and 18.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Onesource Specialty Pharma (formerly Stelis Biopharma) reported Q3 FY26 consolidated revenue of Rs 2,903M, down from Rs 3,758M in Q2 FY26. The company posted a consolidated loss of Rs 887M in Q3 versus profit of Rs 105M in Q2. Standalone revenue dipped to Rs 2,902M from Rs 3,752M QoQ, with a loss of Rs 622M. For 9M FY26, standalone revenue grew around 20 percent year on year to Rs 9,864M. Exceptional charges of Rs 71M in Q3 include employee separation and gratuity impacts under new labour codes. A USD 136M arbitration claim from Prestige Biopharma remains pending at SIAC.
Continued quarterly losses, sequential revenue dip and pending USD 136M arbitration claim could weigh on stock sentiment near term.